author-photo

Christina Schiff

Genentech

23

Papers

1361

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.

2021 European Urology
Show All
- Source
- Cite
- Save
Citations (1)
Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (9)
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial

2020 European Urology
Show All
- Source
- Cite
- Save
Citations (26)
Patient-Reported Outcomes in a Phase 2 Study Comparing Atezolizumab Alone or With Bevacizumab Versus Sunitinib in Previously Untreated Metastatic Renal Cell Carcinoma.

2020 BJUI
Show All
- Source
- Cite
- Save
Citations (7)
Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (21)
Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States

2018
Show All
- Source
- Cite
- Save
Citations (27)
Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

2018 Nature Medicine
Show All
- Source
- Cite
- Save
Citations (487)
IMbassador250: A phase III trial in patients with metastatic castration-resistant prostate cancer (mCRPC) comparing atezolizumab plus enzalutamide vs enzalutamide alone

2018 European Urology Supplements
Show All
- Source
- Cite
- Save
Citations (1)
LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (47)